SOLICITATION NOTICE
B -- Evaluating molecular markers of endometrial cancer in preceding endometrial hyperplasia
- Notice Date
- 7/27/2012
- Notice Type
- Presolicitation
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCi-120131-TG
- Archive Date
- 8/28/2012
- Point of Contact
- Terry Galloway, Phone: 301-402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
gallowaytl@mail.nih.gov, cr214i@nih.gov
(gallowaytl@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6074, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Hormonal and Reproductive Epidemiology Branch (HREB) plans to procure on a sole source basis the services of Kaiser Foundation Research Institute, 1800 Harrison Street, Oakland, CA 94612 to identify tissue blocks from 100 women with endometrial cancer who had a preceding biopsy of endometrial hyperplasia. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The North American Industry Classification System code is 541990 and the business size standard is $7.0 Million. Period of Performance: Performance shall be for the period of twelve (12) months from date of award. It has been determined there are no opportunities to acquire green products or services for this procurement. The Hormonal and Reproductive Epidemiology Branch (HREB) conducts research to identify groups at high risk of cancer, clarify the natural history of various cancers, understand the interactive effects of genetic and environmental factors on cancer risk, and elucidate biologic mechanisms of carcinogenesis. Endometrial cancer is the most common gynecological cancer in the U.S., with an estimated 43,500 incident cases and 8,000 related deaths in 2010. Obesity is a strong risk factor for endometrial cancer, and data in some populations suggest that rates of endometrial cancer and its precursors are rising, mirroring the growing prevalence of obesity. Most endometrial cancers develop slowly through progression of well characterized precursors, many of which regress with progesterone treatment or are curable with hysterectomy. Thus, early detection of endometrial cancer precursors should enable prevention of many endometrial cancers and reduce mortality. Using DNA methylation profiling in NCI studies, the HREB identified a panel of markers that are strongly and specifically linked to endometrial cancer and may have value for early detection. The HREB proposes to evaluate the presence of methylation markers in endometrial hyperplasia samples preceding the diagnosis of endometrial cancer in women participating in the Kaiser Permanente Portland Health Maintenance Organization (HMO). The Contractor is to identify tissue blocks from 100 women with endometrial cancer who had a preceding biopsy of endometrial hyperplasia. After diagnosis of endometrial cancer, women undergo hysterectomy for treatment. The contractor shall retrieve the slides from the hysterectomy specimen containing endometrial cancer, the final endometrial biopsy preceding the hysterectomy and from the first endometrial biopsy and showing endometrial hyperplasia prior to cancer. The study is restricted to cancers diagnosed between 2004-2010 and first biopsies of endometrial hyperplasia occurring in 1987 or later. Eligible cases are further restricted to women with one year or more between the initial diagnosis of hyperplasia and the diagnosis of cancer. The slides will be culled from the surgical pathology files and made available for NCI staff to review on site at Kaiser Permanente, Northwest, Portland, OR. NCI staff will identify key slides and these slides and corresponding formalin fixed paraffin embedded blocks from which they were prepared shall be sent to NCI for histological review and preparation of thick sections (10-20 um); routine sections (5 um) and for cancers, cores for DNA extraction and preparation of tissue microarrays to assess protein expression. The Kaiser Permanente is uniquely qualified to carry out the tasks specified in the procurement being the largest plan in the NCI-supported Cancer Research Network, a consortium of research Health Maintenance Organizations. It is also the earliest established plan (since 1942) among the network of HMOs, ensuring both a large study population size and a sufficient length of follow-up to observe incident cancer diagnosis. Together with the proposed contractor, the NCI has previously conducted a study of endometrial cancers and preceding endometrial hyperplasia. The current proposal serves as an extension of the previous effort, with a stronger focus on extending the collection of tissue for molecular marker studies. Since the NCI has previously sampled from the population at Kaiser Permanente Northwest, the need to extend the efforts in the same population to ensure consistency of findings over time. The contractor has a large and stable patient population, electronic databases for pathology reports and medical treatment information fulfilling the requirements according to highest standards. The NCI knows of no other site has the experience and it would require a considerable effort to establish these procedures at other sites. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI contracting office on or before 11:00 AM EST on August 13, 2012. No electronic capability statements will be accepted (i.e. email or fax), an original and one copy must be sent to the NCI contracting office to the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Terry Galloway, Contract Specialist at gallowaytl@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-120131-TG on all correspondences.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCi-120131-TG/listing.html)
- Record
- SN02818075-W 20120729/120727235911-63ab44fa28b9d7772f45bfefefd7a939 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |